Linked dual-class HIV resistance mutations are associated with treatment failure.

JCI Insight 2019 Oct 3;4(19). Epub 2019 Oct 3.

University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

We hypothesized that HIV-1 with dual-class but not single-class drug resistance mutations linked on the same viral genome, present in the virus population before initiation of antiretroviral therapy (ART), would be associated with failure of ART to suppress viremia. To test this hypothesis, we utilized an ultrasensitive single-genome sequencing assay that detects rare HIV-1 variants with linked drug resistance mutations (DRMs). A case (ART failure) control (nonfailure) study was designed to assess whether linkage of DRMs in pre-ART plasma samples was associated with treatment outcome in the nevirapine/tenofovir/emtricitabine arm of the AIDS Clinical Trials Group A5208/Optimal Combined Therapy After Nevirapine Exposure (OCTANE) Trial 1 among women who had received prior single-dose nevirapine. Ultrasensitive single-genome sequencing revealed a significant association between pre-ART HIV variants with DRMs to 2 drug classes linked on the same genome (dual class) and failure of combination ART with 3 drugs to suppress viremia. In contrast, linked, single-class DRMs were not associated with ART failure. We conclude that linked dual-class DRMs present before the initiation of ART are associated with ART failure, whereas linked single-class DRMs are not.

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.130118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795402PMC
October 2019
1 Read

Publication Analysis

Top Keywords

resistance mutations
12
art failure
12
art associated
8
suppress viremia
8
associated treatment
8
ultrasensitive single-genome
8
single-class drms
8
linked single-class
8
drug resistance
8
single-genome sequencing
8
associated art
8
linked dual-class
8
art
7
linked
7
failure
6
drms
6
associated
5
plasma samples
4
samples associated
4
assess linkage
4

References

(Supplied by CrossRef)
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure
Paredes et al.
J Infect Dis 2010

Similar Publications